Liver Disease News and Research

RSS
Successful RNA interference to turn off multiple genes raises hope for new liver disease treatments

Successful RNA interference to turn off multiple genes raises hope for new liver disease treatments

High prevalence of type 2 diabetes may be linked to excess niacin intake

High prevalence of type 2 diabetes may be linked to excess niacin intake

AlphaRx, Venturepharm sign supply agreement for ARX1088's API

AlphaRx, Venturepharm sign supply agreement for ARX1088's API

Scientists identify protein switch that helps prevent liver cancer

Scientists identify protein switch that helps prevent liver cancer

Researchers to receive more than $4.5 million in grants to study Sudden Infant Death Syndrome

Researchers to receive more than $4.5 million in grants to study Sudden Infant Death Syndrome

Genentech announces positive results from Phase II study of T-DM1

Genentech announces positive results from Phase II study of T-DM1

ImmunoGen announces the presentation of positive trastuzumab-DM1 clinical data

ImmunoGen announces the presentation of positive trastuzumab-DM1 clinical data

Modified blood adult stem-cell transplant regimen reverses sickle cell disease

Modified blood adult stem-cell transplant regimen reverses sickle cell disease

New SPC3649 drug found effective in treating HCV infections

New SPC3649 drug found effective in treating HCV infections

DFG approves establishment of new CRCs; research topics range from modern prostheses to political reforms to marine bacteria

DFG approves establishment of new CRCs; research topics range from modern prostheses to political reforms to marine bacteria

GE Healthcare concentrates on healthymagination to help patients live longer and healthier

GE Healthcare concentrates on healthymagination to help patients live longer and healthier

Comparison study finds no significant differences in post-transplant survival rates of NASH and ETOH groups

Comparison study finds no significant differences in post-transplant survival rates of NASH and ETOH groups

Treatment rates for hepatitis C virus declining, say researchers

Treatment rates for hepatitis C virus declining, say researchers

Study: Impaired oxidation in liver associated with progression to nonalcoholic steatohepatitis

Study: Impaired oxidation in liver associated with progression to nonalcoholic steatohepatitis

Antiviral therapy for hepatitis C appears to be declining in the U.S.; lack of diagnosis is primary barrier to treatment

Antiviral therapy for hepatitis C appears to be declining in the U.S.; lack of diagnosis is primary barrier to treatment

Morbid obesity among people with diabetes is increasing at a very alarming rate, says kidney expert

Morbid obesity among people with diabetes is increasing at a very alarming rate, says kidney expert

EDDA Technology recieves CE Mark for its IQQA-Liver advanced clinical application

EDDA Technology recieves CE Mark for its IQQA-Liver advanced clinical application

Scientists report largest-ever collection of data about the proteins produced by genes in a single human organ

Scientists report largest-ever collection of data about the proteins produced by genes in a single human organ

Study results of nucleoside polymerase and protease inhibitor combination therapy for HCV promising

Study results of nucleoside polymerase and protease inhibitor combination therapy for HCV promising

$3.9 million Challenge grant for Thomas Jefferson researchers

$3.9 million Challenge grant for Thomas Jefferson researchers

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.